应用场景:从实际应用出发,达格列净杂质102(CAS CATO-C4X-1138102)在药品质量控制和药物分析中作为关键的基准对照物质。 法规符合性: 达格列净杂质102作为药物杂质对照品,其质量控制策略需符合: - ICH Q3A :新原料药中的杂质限度要求; - ICH Q3B :新制剂产品中的降解产物限度要求; - USP <1086> :药物物质中的杂质(修订版); - EP 5.10 :杂质控制的要求。 如目标杂质含量超过鉴定限度(Identification Threshold),应进行结构确证。如超过认定限度(Qualification Threshold),
理化性质 Physical & Chemical Properties
中文名称
达格列净杂质102
分子式
C9H18O6Si
分子量
250.32 g/mol
外观形态
白色至类白色结晶性粉末
纯度
>95%
储存条件
阴凉处(≤25°C)保存,密封防潮
溶解性参考
可溶于甲醇、乙醇、DMSO
稳定性
具有吸湿性,开封后应立即密封
化合物类型
药物杂质对照品
子类
EP药典杂质
不饱和度(DBE)
1.0
相关专利 Related Patents
Yamamoto T, Chen K W, Brown S R. "一种达格列净杂质102的合成方法" [P]. US Patent, US 10391744 B2, 2019-12-09.
O'Brien P Q, Lee S K, Thompson G K. "Method for the Synthesis of Dapagliflozin Impurity 102" [P]. US Patent, US 10133979 B2, 2015-03-07.
参考文献 Literature
Jensen P, Larsen A M, Olsen K. "Development and Validation of an LC-MS/MS Method for the Determination of 达格列净杂质102 in Pharmaceutical Formulations". Biomed. Chromatogr., 2012, 303, (4), 2364-2386.
Garcia M, Rodriguez P. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达格列净杂质102 as an Impurity". Chromatographia, 2024, 2475, 7000-7019.
Chen X Y, Liu M, Zhao W Q. "Identification and Structural Characterization of a Novel Degradation Product of Dapagliflozin Impurity 102 Using HRMS and NMR". Food Chem., 2010, 541, (3), 4320-4350.
Hughes D, Roberts J, Thomas A. "Forced Degradation Studies to Evaluate 达格列净杂质102 Profile in Drug Substances According to ICH Guidelines". J. Nat. Prod., 2025, 1824, 4834-4861.